埃罗替尼
表皮生长因子受体
医学
腺癌
表皮生长因子
肿瘤科
癌症研究
胰腺上皮内瘤变
内科学
盐酸厄洛替尼
胰腺癌
癌症
胰腺导管腺癌
受体
作者
Girijesh Kumar Patel,Josiah B Perry,Osama Abdul-Rahim,Arthur E. Frankel,Daniel Cameron,William R. Taylor,Rodney P. Rocconi,Laith Abushahin,Cindy Nelson,Ajay P. Singh,Moh’d Khushman
标识
DOI:10.4103/jcrt.jcrt_729_18
摘要
Despite recent advances in treatment with multidrug chemotherapy regimens, outcomes of patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain very poor. Treatment with targeted therapies has shown marginal benefits due to intrinsic or acquired resistance. Actionable mutations, while detected infrequently in patients with PDAC, are becoming increasingly used in personalized medicine. Here, we describe an epidermal growth factor receptor (EGFR)-activating mutation (E746_T751>VP) to erlotinib, a first-generation tyrosine kinase inhibitor (TKI), in a patient with metastatic PDAC. After an initial partial response to erlotinib for 12 months, the patient's disease progressed with emergence of the EGFR A647T mutation. Certainly, the patient also progressed after switching therapy to a third-generation EGFR TKI (osimertinib). This case illustrates the posttreatment evolution of EGFR A647T-mediated resistance to the first- and third-generation TKIs. To our knowledge, this is the first case to report the aforementioned activating and resistance-mediated mutations. In summary, genomic analysis performed in this patient with PDAC on the tumor biopsy and peripheral blood provided tools to understand mechanisms of response and resistance to targeted therapy with EFGR TKIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI